GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Cyclically Adjusted PS Ratio

BMY (Bristol-Myers Squibb Co) Cyclically Adjusted PS Ratio : 2.33 (As of May. 22, 2025)


View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio?

As of today (2025-05-22), Bristol-Myers Squibb Co's current share price is $47.03. Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $20.15. Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio for today is 2.33.

The historical rank and industry rank for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

BMY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.08   Med: 4.62   Max: 7
Current: 2.33

During the past years, Bristol-Myers Squibb Co's highest Cyclically Adjusted PS Ratio was 7.00. The lowest was 2.08. And the median was 4.62.

BMY's Cyclically Adjusted PS Ratio is ranked worse than
54.14% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs BMY: 2.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bristol-Myers Squibb Co's adjusted revenue per share data for the three months ended in Mar. 2025 was $5.491. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $20.15 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.67 4.21 4.34 2.85 2.88

Bristol-Myers Squibb Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.18 2.67 2.88 3.03

Competitive Comparison of Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.


;
;

Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=47.03/20.15
=2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=5.491/134.9266*134.9266
=5.491

Current CPI (Mar. 2025) = 134.9266.

Bristol-Myers Squibb Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.497 100.684 3.346
201509 2.425 100.392 3.259
201512 2.544 99.792 3.440
201603 2.614 100.470 3.510
201606 2.901 101.688 3.849
201609 2.932 101.861 3.884
201612 3.115 101.863 4.126
201703 2.950 102.862 3.870
201706 3.118 103.349 4.071
201709 3.194 104.136 4.138
201712 3.316 104.011 4.302
201803 3.166 105.290 4.057
201806 3.487 106.317 4.425
201809 3.479 106.507 4.407
201812 3.649 105.998 4.645
201903 3.616 107.251 4.549
201906 3.832 108.070 4.784
201909 3.676 108.329 4.579
201912 4.095 108.420 5.096
202003 4.775 108.902 5.916
202006 4.476 108.767 5.553
202009 4.603 109.815 5.656
202012 4.915 109.897 6.034
202103 4.889 111.754 5.903
202106 5.197 114.631 6.117
202109 5.182 115.734 6.041
202112 5.396 117.630 6.189
202203 5.383 121.301 5.988
202206 5.531 125.017 5.969
202209 5.223 125.227 5.628
202212 5.375 125.222 5.792
202303 5.365 127.348 5.684
202306 5.341 128.729 5.598
202309 5.313 129.860 5.520
202312 5.645 129.419 5.885
202403 5.865 131.776 6.005
202406 6.013 132.554 6.121
202409 5.855 133.029 5.939
202412 6.080 133.157 6.161
202503 5.491 134.927 5.491

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bristol-Myers Squibb Co  (NYSE:BMY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Executives
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samit Hirawat officer: Chief Medical Offr., Drug Dev. BRISTOL-MYERS SQIUBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543